<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060383</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230B2219</org_study_id>
    <secondary_id>2012-002916-16</secondary_id>
    <nct_id>NCT02060383</nct_id>
  </id_info>
  <brief_title>Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly</brief_title>
  <official_title>A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and
      safely managed in majority of patients, including those with diabetes at start of pasireotide
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, multi-center, randomized, open-label study. Eligible patients will start
      pasireotide subcutaneously (s.c.) for Cushing's disease and pasireotide LAR (long-acting
      release) for acromegaly. Patients currently treated at screening visit with pasireotide s.c.
      or LAR are eligible as long as they meet protocol criteria during the screening period. If
      previously normo-glycemic patients experience increases in their fasting blood glucose and
      meeting the criteria for diabetes while on pasireotide, they will start anti-diabetic
      treatment using metformin. If they continue to have elevated blood sugars above target on
      metformin within the first 16 weeks, they will be randomized in a 1:1 ratio to receive
      treatment with incretin based therapy or insulin for approximately 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2014</start_date>
  <completion_date type="Anticipated">April 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from randomization to approximately 16 weeks</measure>
    <time_frame>Randomization, 16 weeks</time_frame>
    <description>HbA1c change from randomization to approximately 16 weeks in the incretin based therapy arm and insulin arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c and FPG (Fasting Plasma Glucose) from randomization over time and to Core EOP (End of Phase) (only for FPG) per randomized arm</measure>
    <time_frame>Randomization, R(randomization)-Week 2, R-Week 4, R-Week 6, R-Week 8, R-Week 10, R-Week 12, R-Week 14, R-Week 16</time_frame>
    <description>The change in HbA1c and FPG from randomization overtime and to the core EOP (only for FPG) will be summarized for each randomized arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who required anti-diabetic rescue therapy with insulin in the incretin based arm</measure>
    <time_frame>Randomization to up to 16 weeks</time_frame>
    <description>The proportion of patients who received anti-diabetic rescue therapy in incretin based therapy will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c and FPG from baseline to Core EOP</measure>
    <time_frame>Baseline, Up to 32 weeks</time_frame>
    <description>Change in HbA1c and FPG from baseline to Core EOP in patients who received pasireotide by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≤ 0.3% HbA1c increase from baseline to Core EOP per randomized arm.</measure>
    <time_frame>Baseline, Up to 32 weeks</time_frame>
    <description>The proportion of patients with an increase from baseline in HbA1c ≤ 0.3% at Core EOP will be summarized for each randomized arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of pasireotide in combination with anti-diabetic treatments</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Number of adverse drug events, overall and by severity and number of serious adverse events and laboratory abnormalities. Also, changes in laboratory assessments, electrocardiograms, vital signs, thyroid function tests and gallbladder examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia events</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Summary of the number of treatment emergent hypoglycemia events, as well as the number of patients with hypoglycemia events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Cushing's Disease</condition>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Incretin based therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to the incretin based arm will start with sitagliptin once daily. If sitagliptin does not control the patient's hyperglycemia, sitagliptin will be stopped and patients will be switched to liraglutide once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to the insulin arm may start with once daily dose of basal insulin. The dose may be up or down titrated at the discretion of the investigator. If blood glucose levels remain uncontrolled on basal insulin, patient may be switched to basal insulin plus prandial insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide s.c.</intervention_name>
    <description>To be administered to Cushing's patients</description>
    <arm_group_label>Incretin based therapy</arm_group_label>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Taken for 16 weeks or until the drug is found to be not effective</description>
    <arm_group_label>Incretin based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Patient will switch to liraglutide if sitagliptin is found to be inefficacious.</description>
    <arm_group_label>Incretin based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Patient will take insulin for 16 weeks.</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide LAR</intervention_name>
    <description>To be administered to acromegaly patients</description>
    <arm_group_label>Incretin based therapy</arm_group_label>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>If previously normo-glycemic patients experience increases in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they will start anti-diabetic treatment using metformin. If they continue to experience increases in their fasting blood glucose within the first 16 weeks, they will be randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks.</description>
    <arm_group_label>Incretin based therapy</arm_group_label>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients greater than or equal to 18 years old

          -  Confirmed diagnosis of Cushing's disease or acromegaly

        Exclusion Criteria:

          -  Patients who require surgical intervention

          -  Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to
             study entry

          -  HbA1c &gt; 10 % at screening

          -  Known hypersensitivity to somatostatin analogues Other protocol-defined
             inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes and Endocrine Associates La Mesa Location</name>
      <address>
        <city>Multiple Locations</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Humphries</last_name>
      <phone>619-466-4899</phone>
      <email>dmendo1@pacbell.net</email>
    </contact>
    <investigator>
      <last_name>Raymond Fink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre SC</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Garcia</last_name>
      <phone>805-658-8460</phone>
      <email>g5garcia@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ronald H. Chochinov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research East Coast Inst. for Res(ECIR)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Green</last_name>
      <email>Miriam.Green@eastcoastresearch.net</email>
    </contact>
    <investigator>
      <last_name>Mae Sheikh-Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University SC - SOM230B2411</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane Clifton</last_name>
      <phone>314-747-3294</phone>
      <email>mclifton@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Silverstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic Great Falls Clinic</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Bowman</last_name>
      <phone>406-771-3373</phone>
      <email>patty.bowman@gfclinic.com</email>
    </contact>
    <investigator>
      <last_name>Barry Cohan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School - Rutgers SC</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah A. McCloskey</last_name>
      <phone>732-418-8484</phone>
      <email>mcclosda@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Lubitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Clinical &amp; Translational Science Ct</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital SC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa L Cohen</last_name>
      <phone>212-241-8903</phone>
      <email>cohenv@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eliza B. Geer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Neuroendocrine Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos C. Reyes-Vidal</last_name>
      <phone>212-305-4921</phone>
      <email>csr52@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela U. Freda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamika Wong</last_name>
      <email>Twong4@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>John Boockvar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates SC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Spiller</last_name>
      <email>kspiller@aghendo.com</email>
    </contact>
    <investigator>
      <last_name>Murray B Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Clinical Trials Center SOM230B2219</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-8210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri L. Dixon</last_name>
      <phone>615-343-0266</phone>
      <email>sheri.dixon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea L. Utz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine Ben Taub General Hosp.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Endocrinology Research SC-2</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jawad M. Khan</last_name>
      <email>jlarocque@VaEndoResearch.org</email>
    </contact>
    <investigator>
      <last_name>James LaRocque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Dept.ofSeattle Neuroscience(2)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriko Courtney</last_name>
      <phone>206-320-7115</phone>
      <email>yuriko.courtney@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Zachary Litvak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-590</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90560-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joinville</city>
        <state>SC</state>
        <zip>89201260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Germering</city>
        <zip>82110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altunizade</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>India</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's disease</keyword>
  <keyword>acromegaly</keyword>
  <keyword>pasireotide</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Pasireotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

